Compare BridgeBio Pharma Inc (BBIO) vs Gitlab Inc (GTLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Gitlab Inc — how do they compare? BridgeBio Pharma Inc trades at $82.34 (market cap $16.46B), while Gitlab Inc trades at $32.69 (market cap $5.57B). The key difference: BridgeBio Pharma Inc is far larger — about 3× Gitlab Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Gitlab Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | GTLB | |
|---|---|---|
Market Cap | $16.46B | $5.57B |
Sector | Health | Technology |
52-Week High | $90.17 | $51.04 |
52-Week Low | $44.81 | $19.42 |
Enterprise Value | $18.02B | $4.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
GitLab (GTLB) trades at $33.47, up 3.24% today, with a bullish technical signal from moving averages and a consensus analyst price target of $31.93. The company reported strong revenue growth to $759.25 million in 2025, though it remains unprofitable with a net margin of -2.49%. Recent news highlights its leadership in DevSecOps and AI-driven platform expansions, including a collaboration with Google Cloud.
The outlook is mixed; robust revenue growth and strategic positioning in AI and DevSecOps offer upside, but profitability challenges and high valuation multiples pose risks. Analyst sentiment is cautious with a majority hold rating, reflecting concerns over near-term execution versus long-term potential in the enterprise software market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
